Biomarker Assay for Stroke Subtype Differential Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for stroke, particularly CT scans, have low sensitivity for ischemic and transient ischemic attacks, necessitating a more accurate and rapid biological fluid-based diagnostic tool to differentiate between hemorrhagic stroke, ischemic stroke, and transient ischemic attack for timely and appropriate treatment.
Innovation Solution
A method involving the determination of biomarkers VCAM-1, GFAP, CRP, and IL-6 concentrations in patient samples, combined with statistical algorithms, to aid in differential diagnosis and treatment decision-making.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CT scan is used for stroke diagnosis, then the diagnostic speed is fast and accessibility is good, but the sensitivity for ischemic stroke and transient ischemic attack is poor
Solution Approach 1:
The patent replaces the mechanical imaging system (CT scan) with a biochemical detection system that measures biomarker concentrations in blood samples. This substitution enables detection of ischemic stroke and TIA through molecular markers (such as neurospecific enolase, beta-amyloid, and other protein biomarkers) rather than relying on structural imaging, thereby achieving high sensitivity for IS and TIA while maintaining rapid diagnostic capability through simple blood tests.
2Measurement precision
If MRI is used for stroke diagnosis, then the sensitivity for IS diagnosis is improved, but the time requirement increases and machine accessibility decreases
Solution Approach 1:
The patent employs a simple, rapid blood-based biomarker assay that can be performed using常规 laboratory equipment rather than expensive, time-consuming MRI machinery. The method uses disposable test kits or assay plates to measure biomarker levels in blood samples, providing high sensitivity for ischemic stroke diagnosis within minutes to hours, thus eliminating the time and accessibility constraints of MRI while maintaining diagnostic precision.
3Measurement precision
If biomarker tests are developed for stroke sub-type differentiation, then the diagnostic accuracy is improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent segments the diagnostic process into distinct biomarker measurements for different stroke sub-types. Each stroke category (ischemic, hemorrhagic, TIA) is associated with specific biomarker profiles - for example, elevated neurospecific enolase and beta-amyloid for ischemic stroke, different protein markers for hemorrhagic stroke. This segmentation allows clinicians to interpret results based on specific biomarker patterns, simplifying the overall diagnostic decision-making while maintaining high accuracy for sub-type differentiation.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.